Goodwin, Aspyrian collaborate on successful GMP manufacturing, IND submission for new ADC platform
Based on achieving this critical milestone, Aspyrian Therapeutics recently submitted and has received FDA’s acceptance of an Investigational New Drug (IND) Application for RM-1929, their first-in-class, precision targeted